openPR Logo
Press release

Hemophilia A Market is Expected to Show a Healthy Growth Rate During the Study Period (2019-2032)| Key Companies - BioMarin Pharmaceutical, Roche, ApcinteX, Novo Nordisk, Sanofi

11-08-2023 09:23 AM CET | Health & Medicine

Press release from: DelveInsight Business Research LLP

Hemophilia A Market

Hemophilia A Market

(Las Vegas, Nevada, United States) "Hemophilia A- Market Insights, Epidemiology and Market Forecast- 2032" by DelveInsight provides a comprehensive analysis of Hemophilia A, including a detailed examination of its historical and projected Hemophilia A epidemiology. Additionally, the report offers insights into the Hemophilia A market trends in the United States, EU-5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan, aiming to enhance the understanding of this condition.

Download the Sample Report to learn more
https://www.delveinsight.com/sample-request/hemophilia-a2030-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr

Hemophilia A Overview
Hemophilia A is a genetic bleeding disorder in which an individual lacks or has low levels of proteins named clotting factor VIII. The mainstay treatment option has long been FVIII replacement therapy. Initially, FVIII replacement was accomplished by donated whole blood, subsequently by plasma, and currently by recombinant human FVIII (rFVIII) replacement therapies, which revolutionized the treatment of Hemophilia A. Although hemophilia is usually diagnosed at birth, the disorder can also be acquired later in life if the body begins to produce antibodies that attack and destroy clotting factors. However, this acquired type of hemophilia is very rare.

Click here to learn more about the Hemophilia A Market Landscape @https://www.delveinsight.com/report-store/hemophilia-a2030-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr

Key Highlight from Hemophilia A Market Report:
The total Hemophilia A market size is 7MM USD 8,510 million in 2021 and is projected to grow during the forecast period (2023-2032).
The total Hemophilia A prevalent population in the 7MM comprised 45,149 cases in 2021 and is projected to increase during the forecast period.
The key Hemophilia A companies working in the treatment landscape include BioMarin Pharmaceutical, Roche, ApcinteX, Novo Nordisk, Sanofi, and many others.
The key Hemophilia A therapies in the pipeline include Concizumab, Fitusiran, BIVV001, Marstacimab and others.

Hemophilia A Treatment Market
About 30% of severe Hemophilia A patients develop neutralizing anti-FVIII alloantibodies (inhibitors), which render the FVIII replacement ineffective. The standard of care therapy for patients with inhibitors is to induce immune tolerance with high-dose, high-frequency FVIII and treatment with bypassing agents (e.g. recombinant activated factor VII such as NOVOSEVEN, FEIBA). There are many approved therapies for the management of Hemophilia A which include HEMLIBRA (for both inhibitor and non-inhibitor), SEVENFACT, KOGENATE FS, FEIBA, KOVALTRY, ELOCTATE, NUWIQ, AFSTYLA, and others.

Learn more about the treatment market for Hemophilia A @ https://www.delveinsight.com/report-store/hemophilia-a2030-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr

The Report Covers the Hemophilia A Epidemiology Segmented by:
Hemophilia A Prevalent cases
Hemophilia A Incident Cases
Hemophilia A treatment cases
Hemophilia A Diagnosed cases

Hemophilia A Dug Profile and Companies Covered
BioMarin Pharmaceutical: Concizumab
Roche Pharmaceuticals: Fitusiran
ApcinteX: BIVV001
Novo Nordisk: Marstacimab
Sanofi: Valrox
And many others.

Learn more about the Key Companies and Emerging Therapies in the Hemophilia Market @ https://www.delveinsight.com/report-store/hemophilia-a2030-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr

Table of Contents
Key Insights
Hemophilia A Introduction
Executive Summary of Hemophilia A
Disease Background and Overview
Hemophilia A Epidemiology and patient population
Hemophilia A Emerging Therapies
Hemophilia A Market Outlook
Hemophilia A Market Access and Reimbursement of Therapies
Hemophilia A Market Drivers
Hemophilia A Market Barriers
Appendix
Hemophilia A Report Methodology
DelveInsight Capabilities
Disclaimer

Learn about the detailed offerings of the Hemophilia A Market Outlook report @ https://www.delveinsight.com/report-store/hemophilia-a2030-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr

Related Reports
Hemophilia A Epidemiology Forecast
https://www.delveinsight.com/report-store/hemophilia-a-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr

Hemophilia A Pipeline Forecast
https://www.delveinsight.com/report-store/hemophilia-a-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr

DelveInsight Business Research LLP
Aditya Kaul
info@delveinsight.com
https://www.delveinsight.com

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Hemophilia A Market is Expected to Show a Healthy Growth Rate During the Study Period (2019-2032)| Key Companies - BioMarin Pharmaceutical, Roche, ApcinteX, Novo Nordisk, Sanofi here

News-ID: 3280348 • Views:

More Releases from DelveInsight Business Research LLP

Myelofibrosis Pipeline Report 2025 by DelveInsight: Key Insights into Clinical Stage Assets, Pharma Collaborations, Regulatory Developments, and the Global Market Growth Prospects
Myelofibrosis Pipeline Report 2025 by DelveInsight: Key Insights into Clinical S …
DelveInsight's "Myelofibrosis Pipeline Insight" report provides comprehensive insights about 35+ companies and 40+ pipeline drugs in the Myelofibrosis pipeline landscape. It covers the Myelofibrosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Myelofibrosis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Stay ahead with the latest insights! Download DelveInsight's comprehensive Myelofibrosis
Hemophilia Pipeline Landscape Report 2025: DelveInsight's Exclusive Report on Current Drug Trials, Potential Breakthrough Therapies, Pharma R&D Initiatives, and Future Market Transformations
Hemophilia Pipeline Landscape Report 2025: DelveInsight's Exclusive Report on Cu …
DelveInsight's "Hemophilia Pipeline Insight" report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in the Hemophilia pipeline landscape. It covers the Hemophilia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hemophilia therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Stay ahead with the latest insights! Download DelveInsight's comprehensive Hemophilia
DelveInsight's NMIBC Pipeline 2025: Unveiling Drug Development Progress, Clinical Advances, Pharma Strategies, and Market Evolution
DelveInsight's NMIBC Pipeline 2025: Unveiling Drug Development Progress, Clinica …
DelveInsight's, "Non Muscle Invasive Bladder Cancer Pipeline Insight" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Non Muscle Invasive Bladder Cancer pipeline landscape. It covers the Non Muscle Invasive Bladder Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Non Muscle Invasive Bladder Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive
Hearing Loss Pipeline 2025 by DelveInsight: Exploring Novel Mechanisms of Action, Ongoing Clinical Trials, Pharma Collaborations, and the Future Outlook of the Therapeutics Landscape
Hearing Loss Pipeline 2025 by DelveInsight: Exploring Novel Mechanisms of Action …
DelveInsight's "Hearing Loss Pipeline Insight" report provides comprehensive insights about 32+ companies and 35+ pipeline drugs in Hthe earing Loss pipeline landscape. It covers the Hearing Loss pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hearing Loss therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Stay ahead with the latest insights!

All 5 Releases


More Releases for Hemophilia

Rising Occurrence Of Genetic Abnormalities Fuels Hemophilia Market Growth: Stren …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts What Is the Expected CAGR for the Hemophilia Market Through 2025? In recent times, there has been a significant expansion in the hemophilia market. The market, which stood at $13.83 billion in 2024, is projected to inflate to $15.13 billion in 2025, exhibiting a compound annual growth rate (CAGR)
Global Hemophilia Market Size & Trends
According to a new market research report published by Global Market Estimates, the global hemophilia market is projected to grow at a CAGR of 6.8% from 2023 to 2028. During the forecast period, the global hemophilia market is anticipated to experience growth due to advancements in medical research, an increase in hemophilia incidence, and rising awareness and diagnosis. Browse 147 Market Data Tables and 115 Figures spread through 163 Pages and
Acquired Hemophilia Treatment Market - Embracing Hope, Defying Hemophilia: Trans …
Newark, New Castle, USA: The "Acquired Hemophilia Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors Acquired Hemophilia Treatment Market: https://www.growthplusreports.com/report/acquired-hemophilia-treatment-market/7748 This latest report researches the industry structure,
Hemophilia Market
Hemophilia is an inherited genetic syndrome which impairs body-2019s capability to control blood clotting or coagulation. The episodes of bleeding mainly depend on the severity of hemophilia issue. There are two major kinds of hemophilia namely Hemophilia A & Hemophilia B. Hemophilia A is considered to be five times more prevailing as compared to hemophilia B. Occurrence of hemophilia A is found in one out of five or six thousand
Global Hemophilia Therapeutics Market By Drug (Advate, NovoSeven, Kogenate/Koval …
ReportsWorldwide has announced the addition of a new report title Global Hemophilia Therapeutics Market By Drug (Advate, NovoSeven, Kogenate/Kovaltry, Feiba), By Type of Hemophilia (Hemophilia A, Hemophilia B), By Treatment (On-Demand, Prophylaxis), By Therapy (Replacement , Immune Tolerance Induction ) Outlook 2022 to its growing collection of premium market research reports. Hemophilia is an inherited bleeding disorder that slows the blood clotting process. The people suffering from this condition experience prolonged
In-depth analysis of the Global Hemophilia Market: hemophilia A, hemophilia B, h …
Latest industry research report on: Global Hemophilia Market | Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts Request For Sample Report @ http://www.marketresearchreports.biz/sample/sample/1064504 The hemophilia market has entered into an era of unprecedented growth rate with a variety of treatment options. Development of new therapeutics along with expansion in the current treatment options has presented new opportunities to the market. Hemophilia being an inherited genetic bleeding disorder causes